← All Wave Life Sciences LTD filings

Wave Life Sciences LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
WVE
Wave Life Sciences LTD
10-K/A: Wave Life Sciences Files 10-K/A Amendment
Wave Life Sciences Ltd. filed an amendment to its 2025 Annual Report to include required Part III disclosures and updated certifications.
NASDAQ
WVE
Wave Life Sciences LTD
10-K: Wave Life Sciences Reports Mixed 2025 Results Amid Clinical Progress
Wave Life Sciences reported increased net losses in 2025 despite positive clinical trial data for its lead RNA medicine programs and a significant capital raise.
NASDAQ
WVE
Wave Life Sciences LTD
10-K/A: Wave Life Sciences Files Amendment No. 1 to Form 10-K/A: Updates on Executive Compensation and Corporate Governance
Wave Life Sciences Ltd. files an amendment to its 2024 annual report, primarily to include previously omitted information regarding executive compensation, corporate governance, and updated certifications.
NASDAQ
WVE
Wave Life Sciences LTD
10-K: Wave Life Sciences Reports 2024 Results, Highlights RNA Medicine Pipeline Progress
Wave Life Sciences' 10-K filing summarizes the company's focus on RNA medicines, clinical program advancements, and financial results for the year ended December 31, 2024.
NASDAQ
WVE
Wave Life Sciences LTD
10-K/A: Wave Life Sciences Amends Annual Report to Include Omitted Information
Wave Life Sciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and updated certifications.
NASDAQ
WVE
Wave Life Sciences LTD
10-K: Wave Life Sciences Details Share Structure and Governance in 10-K Filing
Wave Life Sciences' 10-K filing provides a detailed overview of its share capital, governance, and shareholder rights, highlighting its focus on RNA medicines.